Growth inhibition of cervix carcinoma cells in vivo by endothelin a receptor blockade

Anna Bagnato, Alessia Cirilli, Debora Salani, Paola Simeone, Antonio Muller, Maria Rita Nicotra, Pier Giorgio Natali, Aldo Venuti

Research output: Contribution to journalArticlepeer-review


In human papillomavirus (HPV)-positive cervical cancer cells, the endothelin A receptor (ETAR) mediates an endothelin-l-induced mitogenic effect, thus representing a relevant target for antitumor therapy. Here, we describe the complete inhibition of human cervix carcinoma growth by blocking the ETAR. In nude mice, the ETAR-selective antagonist atrasentan inhibits the growth and the neoangiogenesis of cervical carcinoma cell xenografts. Two cycles of treatment completely revert tumor growth. Atrasentan displays additive effects when administered in combination with the cytotoxic drug paclitaxel. These results demonstrate that by inhibiting cell proliferation and angiogenesis, this small molecule may help to control cervical cancer by either monotherapy or combination therapy.

Original languageEnglish
Pages (from-to)6381-6384
Number of pages4
JournalCancer Research
Issue number22
Publication statusPublished - Nov 15 2002

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Growth inhibition of cervix carcinoma cells in vivo by endothelin a receptor blockade'. Together they form a unique fingerprint.

Cite this